Search
for

    Did you mean Clascoterone?
    GlossaryClascoterone

    topical medication that blocks androgen receptors to treat hair loss

    Clascoterone is a topical medication used to treat acne and androgenetic alopecia (a common form of hair loss). It works by blocking androgen receptors in the skin, which helps reduce the effects of hormones like testosterone that can contribute to these conditions.

    Related Terms

    Learn

    3 / 3 results

      learn Clascoterone

      a novel topical treatment that inhibits DHT on androgen receptors

      learn KY19382

      compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles

    Research

    5 / 49 results

    Community Join

    5 / 124 results

      community Breezula hasn't even begun phase 3 trials yet. F*cking hell.

      in Treatment  44 upvotes 3 years ago
      The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.

      community Winlevi coming out in 2019

       14 upvotes 6 years ago
      The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.

      community Don’t Get Too Hyped About PP405. We've Seen This Movie Before.

      in Research/Science  211 upvotes 1 month ago
      PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  7 upvotes 2 weeks ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.